CD8A and neoplasm: The results showed that the highest frequency of CD8+TEM and CD4+TEM while the lowest frequency of the CD8+TCM and CD4+TCM were observed in the cured mice, demonstrating the ability of the combinational therapeutic strategy to effectively turn CD8+TCM and CD4+TCM into a TEM phenotype, which could provide more‐potent antitumor immune memory responses to protect against tumor re‐challenge (Figure 6G,H and Figure S18, Supporting Information).